Welcome to LookChem.com Sign In|Join Free

CAS

  • or

139194-79-9

Post Buying Request

139194-79-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

139194-79-9 Usage

Description

3-Bromo-5-nitrobenzyl alcohol is a chemical compound characterized by the molecular formula C7H6BrNO3. It is a white to off-white crystalline solid that serves as a versatile building block and reagent in the realm of organic synthesis. 3-Bromo-5-nitrobenzyl alcohol features a benzene ring with a bromine atom and a nitro group, complemented by an alcohol functional group, making it a valuable intermediate in the synthesis of pharmaceuticals, agrochemicals, and various organic materials. However, it is also recognized for its potential mutagenic and carcinogenic properties, necessitating careful handling and usage in both laboratory and industrial environments.

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-nitrobenzyl alcohol is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of drug molecules, contributing to the development of new medications and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-nitrobenzyl alcohol is employed as a precursor in the production of pesticides and other agrochemicals. Its reactivity and functional groups enable the synthesis of effective compounds designed to protect crops and enhance agricultural productivity.
Used in Organic Material Synthesis:
3-Bromo-5-nitrobenzyl alcohol is used as a versatile intermediate for the synthesis of organic materials, including dyes, polymers, and other specialty chemicals. Its structural features facilitate the development of innovative materials with unique properties and applications.
Used in Research and Development:
3-Bromo-5-nitrobenzyl alcohol is also employed in research and development settings, where its reactivity and structural attributes are harnessed to explore new chemical reactions and syntheses. This contributes to the advancement of organic chemistry and the discovery of novel compounds with potential applications across various industries.

Check Digit Verification of cas no

The CAS Registry Mumber 139194-79-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,1,9 and 4 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 139194-79:
(8*1)+(7*3)+(6*9)+(5*1)+(4*9)+(3*4)+(2*7)+(1*9)=159
159 % 10 = 9
So 139194-79-9 is a valid CAS Registry Number.

139194-79-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name (3-bromo-5-nitrophenyl)methanol

1.2 Other means of identification

Product number -
Other names 3-nitro-5-bromobenzyl alcohol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:139194-79-9 SDS

139194-79-9Relevant articles and documents

A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove

Bonnar, James,Dixon, Ian,Evison, Benny J.,Kelly, Graham E.,Kumar, Sanjay,Lambert, Gilles,Nativel, Brice,Palmer, James T.,Parmar, Jasneet,Rathi, Anuj Kumar,Suchowerska, Alexandra K.,Tang, Wei,Teng, Yanfen,Treutlein, Herbert,Wang, Jie,Xu, Yanfeng,Zeng, Jun,Zhu, Qing,Chemello, Kévin

, (2020/02/13)

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low density lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small molecule inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavourable for binding by small organic molecules. Despite its challenging nature, we report herein the discovery of compound 3f as a small molecule inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chemistry, 3f emerged as a lead-like molecule by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered subcutaneously in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small molecule inhibitor against PCSK9 is therapeutically viable.

Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same

-

, (2019/05/04)

The present invention relates to a pyrimidine compound having excellent FLT3 inhibitory activity, and a pharmaceutical composition for preventing or treating a cancer, including the same. The pyrimidine compound is represented by chemical formula 14, wherein the pyrimidine compound is selected from a stereoisomer, a tautomer, a solvate, and a pharmaceutically acceptable salt thereof. In the chemical formula 14, E^a is hydrogen, hydroxy or C_(1-4) alkoxy, and E^b is hydrogen, halogen, C_(1-4) alkyl or C_(1-4) fluoroalkyl.COPYRIGHT KIPO 2019

Switchable 3D networks by light controlled π-stacking of azobenzene macrocycles

Reuter, Raphael,Wegner, Hermann A.

, p. 146 - 148 (2013/02/23)

Azobenzene macrocycles were designed for switchable π-stacking interaction. After efficient preparation and characterization of azobenzene macrocycles containing electron rich as well as electron poor elements a dimeric analogue was synthesized, which formed reversibly 3D-networks. Gel formation was observed with aromatic solvents representing the first example of this type based on switchable azobenzene macrocycles. The Royal Society of Chemistry.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 139194-79-9